Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

Background: We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors (PEMBIB trial; NCT02856425). Methods: In this monocentric phase Ib dose esc...

Full description

Bibliographic Details
Main Authors: Abbassi, A. (Author), Adam, J. (Author), Bahleda, R. (Author), Baldini, C. (Author), Bigorgne, A. (Author), Boselli, L. (Author), Bredel, D. (Author), Cassard, L. (Author), Champiat, S. (Author), Chaput, N. (Author), Danlos, F.-X (Author), Escriou, G. (Author), Farhane, S. (Author), Gazzah, A. (Author), Grivel, J. (Author), Grynszpan, L. (Author), Halse, H. (Author), Hollebecque, A. (Author), Lacroix, L. (Author), Laghouati, S. (Author), Marabelle, A. (Author), Martin-Romano, P. (Author), Massard, C. (Author), Michot, J.-M (Author), Mohamed-Djalim, C. (Author), Mouraud, S. (Author), Parpaleix, A. (Author), Postel-Vinay, S. (Author), Rafie, S. (Author), Ribrag, V. (Author), Signolle, N. (Author), Soria, J.-C (Author), Susini, S. (Author), Texier, M. (Author), Varga, A. (Author), Vuagnat, P. (Author), Zitvogel, L. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Anti PD-1
Anti-angiogenic
Dose escalation
Immunotherapy
Phase I
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items